Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register
Authors:
- S PetersennSPS Petersenn
- M BuchfelderMBM Buchfelder
- H FranzH Franz
- Participants Of The German Acromegaly RegisterPRParticipants Of The German Acromegaly Register
Open Access
- 1 November 2008
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 159 (5) , 525-532
Abstract
Background: Data on surgical and medical treatment outcomes in acromegaly mostly originate from specialized centers. We retrospectively analyzed the data on surgery, primary somatostatin analog (SSA) therapy, surgery preceded by SSA, and SSA preceded by surgery in 1485 patients from the German Acromegaly Register.Methods: Two trained nurses visited all centers (N=42) for data acquisition.Results: Primary surgery: out of 889 patients, 554 yielded analyzable data (microadenomas 22.9%, macroadenomas 77.1%). GH and IGF1 normalized in 54.3 and 67.2%. Partial or total pituitary insufficiency occurred in 28.6% initially and 41.2% post-surgery. Primary SSA (≥3 months): out of 329 patients, 145 yielded analyzable data (microadenomas 26.7%, macroadenomas 73.3%). GH and IGF1 normalized in 36.3 and 30.5%, increasing to 40.8 and 41.5% with longer SSA (≥360 days) in 54 patients. Pituitary function did not change. SSA (≥3 months) prior to surgery: out of 234 patients, 93 yielded analyzable data. Post-surgery GH and IGF1 was normalized in 62.9 and 68.4%. GH improvement was slightly, but significantly better after SSA pretreatment. Surgery followed by SSA: out of 122 patients, 34 yielded analyzable data. GH and IGF1 normalized during SSA in 24.1 and 45.5%. Relative GH decrease was significantly larger compared with primary SSA.Conclusions: Pituitary surgery was more effective to lower GH and IGF1 concentrations than primary SSA. Primary SSA may be an option in selected patients. SSA prior to surgery only marginally improved surgical outcome. Debulking surgery may result in better final outcome in patients with a high GH concentration and a large tumor.Keywords
This publication has 36 references indexed in Scilit:
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease statusClinical Endocrinology, 2006
- Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institutionClinical Endocrinology, 2005
- Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control studyActa Neurochirurgica, 2005
- Outcome of Surgery for Acromegaly Performed by Different Surgeons: Importance of Surgical ExperiencePituitary, 2005
- Current Status and Future Opportunities for Controlling AcromegalyPituitary, 2002
- Gender and age influence the relationship between serum GH and IGF‐I in patients with acromegalyClinical Endocrinology, 2002
- Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeonQJM: An International Journal of Medicine, 1999
- Does Octreotide Treatment Improve the Surgical Results of Macro-Adenomas in Acromegaly? A Randomized StudyActa Neurochirurgica, 1999
- Assessment of GH status in acromegaly using serum growth hormone, serum insulin‐like growth factor‐I and urinary growth hormone excretionClinical Endocrinology, 1995